Jared Kaltwasser

Oral doses of 3 Janus kinase inhibitors show the therapies out-performed placebo in all outcomes measured in patients with moderate-to-severe AD.

About half of a cohort of nearly 800 patients said they experience ocular symptoms.

Most research into the rare condition is focused on therapies and diagnostics, but investigators say it is important to better understand the disease’s impact on those around the patient.

The new analysis suggests the infections rarely leads to discontinuation in patients with atopic dermatitis.

A new study suggests a close examination of the medical histories of patients with generalized pustular psoriasis can make clear which are most likely to die or be hospitalized in the ICU.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

New data affirms a low rate of hepatitis B vaccination responsiveness among patients with hepatitis B core antibodies.

Direct-acting antivirals have been a major milestone in the treatment of hepatitis C virus, new data show they also work in nearly all children, without serious adverse events.

More than 90% of patients with hepatitis C who sought care at a comprehensive community health clinic completed treatment, and three-quarters of those returned for sustained virologic response testing.

Most patients who were treated with direct-acting antivirals for hepatitis C virus infection saw improvement in oral lichen planus symptoms, including 6 of 10 who saw complete remission.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

The therapy could offer a therapeutic option with a better safety profile, investigators said.

Some fear repeated injections of anti-VEGF drugs might harm retinal nerve fiber layer, but a new study finds little evidence of such harm.

Patients who underwent the therapy also had greater myopic shift compared to those that did not.

The launch of a My Retina Tracker dramatically increased testing rates, which could help lead to better clinical trials and therapies.

The authors of a research letter say a small minority of patients with diabetes have facial pain that cannot otherwise be easily explained.

Study finds team collaboration could also help primary care practices deal with an expected boom in the number of elderly people with chronic conditions.

Helen R. Murphy, MD, explains that physicians who take a proactive approach to diabetes management in women planning to become pregnant can make meaningful reductions in risk.

In the five-year post-program assessment, those who regained their lost weight still saw improvements in liver function.

The new study underscores the importance of annual urine analysis to catch signs of diabetic nephropathy.

Tubeless subcutaneous insulin injection devices are easier to use, but new data suggest they can also improve A1C outcomes.

Parents who knew their children were at higher risk of type 1 diabetes were able to get the condition diagnosed before serious complications developed.

New data suggests a clear benefit to adjuvanted flu vaccines in elderly populations.

In most scenarios, patients with diabetes said they would use remote digital monitoring to manage their disease if the monitoring were equally or somewhat more effective than their current monitoring.

A phase 2 study suggests treating the common diabetes comorbidity may be capable with the monoclonal antibody.

A new study finds benefit to hemoglobin A1c reductions made following conception.

The new federal asthma management guidelines mark the first update of the guidance since 2007.

Many patients with paradoxical vocal fold motion disorder are misdiagnosed, and instead believe they are dealing with asthma. But in many cases, their symptoms do not respond to therapies.

New research adds to the case that some children are genetically more susceptible to allergic disease.

Screening for hepatitis B virus has become the norm in patients about to undergo anti-tumor-necrosis factor α therapy, but new research finds the risk of reactivation of resolved infections is low.